# AutoReviewer Report

> Calibration warning: this run reproduces the Nature pipeline structure, but substitutes
> DeepSeek V4 Flash for the paper's validated o4-mini model. Its scores are not human-calibrated.

- Paper: B152.txt
- Model: deepseek-v4-flash
- Final decision: **Reject**
- Overall: **3/10**
- Confidence: **4/5**
- Independent decisions: {'Accept': 0, 'Reject': 5}
- Estimated API cost: **$0.024400**

## Final Meta-review

The paper proposes AReUReDi, a multi-objective discrete sequence optimization algorithm built on Rectified Discrete Flows (ReDi). It extends ReDi with Tchebycheff-style scalarization, locally balanced proposals, and annealed Metropolis-Hastings updates to bias generation toward Pareto-optimal states. The authors claim theoretical guarantees of invariance, convergence to the Pareto front, and full Pareto-front coverage. Experiments target wild-type peptide binder design and SMILES-based chemically modified peptide design, optimizing up to five predicted therapeutic properties. The method is compared against evolutionary multi-objective baselines (NSGA-III, SPEA2, SMS-EMOA, MOPSO) and a discrete diffusion baseline (PepTune), reporting improved average property scores, along with ablations on rectification, annealing, and guidance strength.

### Scores

| Dimension | Final | Five-review mean | SD | Range |
|---|---:|---:|---:|---:|
| Originality | 2 | 2.400 | 0.490 | 2-3 |
| Quality | 2 | 1.800 | 0.400 | 1-2 |
| Clarity | 2 | 2.000 | 0.000 | 2-2 |
| Significance | 2 | 2.200 | 0.400 | 2-3 |
| Soundness | 2 | 1.800 | 0.400 | 1-2 |
| Presentation | 2 | 2.000 | 0.000 | 2-2 |
| Contribution | 2 | 2.000 | 0.000 | 2-2 |
| Overall | 3 | 3.400 | 0.490 | 3-4 |
| Confidence | 4 | 3.800 | 0.400 | 3-4 |

### Strengths

- The problem of multi-objective discrete sequence design for biomolecular engineering is important and timely.
- The combination of rectified discrete flows, Tchebycheff scalarization, locally balanced proposals, and annealed MCMC corrections is conceptually novel and technically nontrivial.
- The empirical scope is broad: multiple protein targets, different sequence lengths, both amino-acid and SMILES representations, up to five objectives, and comparisons against several established baselines.
- Ablation studies provide insight into the effects of rectification, annealing schedule, and guidance strength on generation quality and objective scores.

### Weaknesses

- The theoretical guarantees are not sound: the detailed-balance proof ignores the state-dependence of the ReDi transition probabilities, Tchebycheff maximizers are not necessarily Pareto-optimal, and the coverage theorem relies on weight randomization that is not used in the experiments.
- The monotonicity constraint used in all main experiments breaks detailed balance and invalidates the stated invariance and convergence results; no alternative theoretical justification is provided for the actual algorithm.
- All evaluation is in silico using approximate property predictors with modest validation accuracy (e.g., hemolysis F1=0.58, affinity Spearman=0.64, half-life trained on only 105 entries); no wet-lab validation is conducted, so biological significance is unverified.
- The multi-objective evaluation is weak: only average per-objective scores are reported, omitting standard metrics such as hypervolume, IGD, or Pareto-front visualization, and no statistical significance tests are provided.
- The method is computationally expensive (55-195 seconds per binder vs. 8-37 seconds for evolutionary baselines), and no runtime or scaling analysis is given for larger sequence spaces.
- Reproducibility is hindered by redacted code/data and algorithm pseudocode, incomplete experimental details, and numerous typos/inconsistencies (e.g., duplicate labels in Table 1).

### Questions

- How is detailed balance derived when the proposal distribution includes the ReDi marginal p_t^i(y|x_t), which is not symmetric and changes with the state? Please provide a corrected proof or clarify the assumptions.
- Does the monotonicity constraint preserve any formal convergence guarantee? If not, can the method be evaluated without this constraint to validate the theoretical claims?
- What are the hypervolume or IGD values achieved by AReUReDi compared to baselines, and how close do the generated solutions get to the true Pareto front?
- How were the Tchebycheff weight vectors chosen in the experiments, and how does the method ensure full Pareto-front coverage when weights are fixed?
- Given the low F1/correlation of several property predictors, how confident are the authors that the designed peptides would exhibit the desired properties experimentally? Are any wet-lab validations planned?

### Limitations

- The theoretical convergence guarantees are asymptotic and apply only to an idealized unconstrained chain; the finite annealed schedule and monotonicity constraint break these guarantees in practice.
- The full Pareto-front coverage is not demonstrated empirically; the reported results are limited to average per-objective scores without front indicators.
- The method relies on in-house surrogate predictors of modest accuracy, and no experimental validation of the designed sequences is provided.
- The computational cost is high, limiting scalability to large sequence libraries or high-throughput design scenarios.
- The method is demonstrated only on peptides and peptide SMILES; applicability to other discrete modalities (DNA, RNA, antibodies) is untested.

### Ethics

Ethical concerns flagged: **False**

## Usage and Cost

- Requests: 6
- Prompt tokens: 129,127
- Cache-hit prompt tokens: 4,096
- Cache-miss prompt tokens: 125,031
- Completion tokens: 24,588
- Reasoning tokens reported: 17,933
- Total tokens: 153,715
- Estimated total: $0.02440045

Full individual reviews and raw JSON responses are in `review_bundle.json`.
